Do analysts rate PETV or ALUR?

Allurion Technologies has a consensus target price of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Allurion Technologies is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to PETV or ALUR?

In the previous week, PetVivo and PetVivo both had 1 articles in the media. PetVivo's average media sentiment score of 0.00 equaled Allurion Technologies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allurion Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALUR or MLSS?

In the previous week, Milestone Scientific had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for Milestone Scientific and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 0.00 equaled Milestone Scientific'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allurion Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Scientific 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend POAI or ALUR?

Allurion Technologies has a consensus price target of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Allurion Technologies is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor ALUR or PSTV?

In the previous week, Plus Therapeutics had 2 more articles in the media than Allurion Technologies. MarketBeat recorded 3 mentions for Plus Therapeutics and 1 mentions for Allurion Technologies. Plus Therapeutics' average media sentiment score of 0.62 beat Allurion Technologies' score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allurion Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Allurion Technologies (ALUR) Competitors

$0.58 0.00 (0.00%)

As of 06/17/2026

Compare

ALUR vs. NSPR, PETV, MLSS, POAI, and PSTV

Should you buy Allurion Technologies stock or one of its competitors? MarketBeat compares Allurion Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allurion Technologies include InspireMD (NSPR), PetVivo (PETV), Milestone Scientific (MLSS), Predictive Oncology (POAI), and Plus Therapeutics (PSTV). These companies are all part of the "medical equipment" industry.

How does Allurion Technologies compare to InspireMD?

Allurion Technologies (NYSE:ALUR) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Allurion Technologies currently has a consensus target price of $45.00, indicating a potential upside of 7,658.62%. InspireMD has a consensus target price of $4.50, indicating a potential upside of 525.87%. Given Allurion Technologies' higher probable upside, equities analysts plainly believe Allurion Technologies is more favorable than InspireMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Allurion Technologies has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market. Comparatively, InspireMD has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by insiders. Comparatively, 34.1% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Allurion Technologies has a net margin of -199.96% compared to InspireMD's net margin of -413.96%. Allurion Technologies' return on equity of 0.00% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
InspireMD	-413.96%	-69.42%	-57.68%

Allurion Technologies has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A
InspireMD	$10.85M	3.10	-$19.92M	-$0.73	N/A

In the previous week, Allurion Technologies had 1 more articles in the media than InspireMD. MarketBeat recorded 1 mentions for Allurion Technologies and 0 mentions for InspireMD. Allurion Technologies' average media sentiment score of 0.00 equaled InspireMD'saverage media sentiment score.

Company	Overall Sentiment
Allurion Technologies	Neutral
InspireMD	Neutral

Summary

InspireMD beats Allurion Technologies on 8 of the 15 factors compared between the two stocks.

How does Allurion Technologies compare to PetVivo?

PetVivo (NASDAQ:PETV) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

PetVivo has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

Allurion Technologies has a net margin of -199.96% compared to PetVivo's net margin of -902.82%. Allurion Technologies' return on equity of 0.00% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Allurion Technologies	-199.96%	N/A	-77.13%

Allurion Technologies has a consensus target price of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Allurion Technologies is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, PetVivo and PetVivo both had 1 articles in the media. PetVivo's average media sentiment score of 0.00 equaled Allurion Technologies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allurion Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Allurion Technologies has higher revenue and earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	27.31	-$10.95M	-$0.38	N/A
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 10.8% of PetVivo shares are owned by insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Allurion Technologies beats PetVivo on 9 of the 14 factors compared between the two stocks.

How does Allurion Technologies compare to Milestone Scientific?

Allurion Technologies (NYSE:ALUR) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Allurion Technologies currently has a consensus price target of $45.00, indicating a potential upside of 7,658.62%. Milestone Scientific has a consensus price target of $1.00, indicating a potential upside of 153.49%. Given Allurion Technologies' higher possible upside, equities analysts clearly believe Allurion Technologies is more favorable than Milestone Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Milestone Scientific has lower revenue, but higher earnings than Allurion Technologies. Milestone Scientific is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A
Milestone Scientific	$8.90M	3.92	-$6.93M	-$0.05	N/A

Milestone Scientific has a net margin of -52.01% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat Milestone Scientific's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Milestone Scientific	-52.01%	-60.26%	-40.23%

Allurion Technologies has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market. Comparatively, Milestone Scientific has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by insiders. Comparatively, 9.2% of Milestone Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Milestone Scientific had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for Milestone Scientific and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 0.00 equaled Milestone Scientific'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allurion Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Scientific	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Milestone Scientific beats Allurion Technologies on 9 of the 14 factors compared between the two stocks.

How does Allurion Technologies compare to Predictive Oncology?

Predictive Oncology (NASDAQ:POAI) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Allurion Technologies has higher revenue and earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	15.01	-$12.66M	-$13.50	N/A
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A

Allurion Technologies has a net margin of -199.96% compared to Predictive Oncology's net margin of -5,065.23%. Allurion Technologies' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Allurion Technologies	-199.96%	N/A	-77.13%

In the previous week, Allurion Technologies had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 1 mentions for Allurion Technologies and 0 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.00 equaled Allurion Technologies'average media sentiment score.

Company	Overall Sentiment
Predictive Oncology	Neutral
Allurion Technologies	Neutral

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by company insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Predictive Oncology has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market.

Allurion Technologies has a consensus price target of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Allurion Technologies is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Allurion Technologies beats Predictive Oncology on 13 of the 15 factors compared between the two stocks.

How does Allurion Technologies compare to Plus Therapeutics?

Allurion Technologies (NYSE:ALUR) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

In the previous week, Plus Therapeutics had 2 more articles in the media than Allurion Technologies. MarketBeat recorded 3 mentions for Plus Therapeutics and 1 mentions for Allurion Technologies. Plus Therapeutics' average media sentiment score of 0.62 beat Allurion Technologies' score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allurion Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Allurion Technologies has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Allurion Technologies has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A
Plus Therapeutics	$5.21M	5.51	-$22.39M	-$2.30	N/A

Allurion Technologies has a net margin of -199.96% compared to Plus Therapeutics' net margin of -230.24%. Allurion Technologies' return on equity of 0.00% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Allurion Technologies currently has a consensus price target of $45.00, indicating a potential upside of 7,658.62%. Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,252.52%. Given Allurion Technologies' higher possible upside, research analysts plainly believe Allurion Technologies is more favorable than Plus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Allurion Technologies beats Plus Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Allurion Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALUR vs. The Competition

Export

Metric	Allurion Technologies	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$8.70M	$8.82B	$7.05B	$23.46B
Dividend Yield	N/A	2.54%	2.68%	4.02%
P/E Ratio	-0.05	16.09	27.12	31.08
Price / Sales	0.51	7.04	587.25	19.77
Price / Cash	N/A	18.40	29.22	18.64
Price / Book	-0.02	3.57	10.89	4.77
Net Income	-$7.20M	$228.19M	$3.58B	$1.06B
7 Day Performance	N/A	-2.31%	-2.11%	-0.23%
1 Month Performance	-94.14%	-0.62%	3.28%	-0.11%
1 Year Performance	-98.66%	-2.73%	26.33%	16.46%

Allurion Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALUR Allurion Technologies	1.1077 of 5 stars	$0.58 flat	$45.00 +7,658.6%	-98.6%	$8.70M	$17.21M	N/A	501
NSPR InspireMD	3.3619 of 5 stars	$0.72 +1.9%	$4.50 +525.0%	-69.5%	$33.72M	$10.85M	N/A	50
PETV PetVivo	N/A	$0.82 +2.4%	N/A	-3.8%	$30.79M	$1.05M	N/A	20
MLSS Milestone Scientific	1.1347 of 5 stars	$0.34 -3.6%	$1.00 +196.5%	-40.8%	$29.83M	$8.90M	N/A	30
POAI Predictive Oncology	N/A	$8.41 +18.8%	N/A	-37.9%	$28.54M	$1.66M	N/A	30	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ALUR) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allurion Technologies (ALUR) Competitors

ALUR vs. NSPR, PETV, MLSS, POAI, and PSTV

How does Allurion Technologies compare to InspireMD?

Summary

How does Allurion Technologies compare to PetVivo?

Summary

How does Allurion Technologies compare to Milestone Scientific?

Summary

How does Allurion Technologies compare to Predictive Oncology?

Summary

How does Allurion Technologies compare to Plus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALUR vs. The Competition

Allurion Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allurion Technologies (ALUR) Competitors

ALUR vs. NSPR, PETV, MLSS, POAI, and PSTV

How does Allurion Technologies compare to InspireMD?

Do analysts rate ALUR or NSPR?

Which has more risk and volatility, ALUR or NSPR?

Do insiders and institutionals have more ownership in ALUR or NSPR?

Is ALUR or NSPR more profitable?

Which has preferable valuation & earnings, ALUR or NSPR?

Does the media prefer ALUR or NSPR?

Summary

How does Allurion Technologies compare to PetVivo?

Which has more risk & volatility, PETV or ALUR?

Is PETV or ALUR more profitable?

Do analysts rate PETV or ALUR?

Does the media refer more to PETV or ALUR?

Which has higher earnings and valuation, PETV or ALUR?

Do insiders & institutionals believe in PETV or ALUR?

Summary

How does Allurion Technologies compare to Milestone Scientific?

Do analysts recommend ALUR or MLSS?

Which has stronger valuation & earnings, ALUR or MLSS?

Is ALUR or MLSS more profitable?

Which has more volatility and risk, ALUR or MLSS?

Do institutionals and insiders believe in ALUR or MLSS?

Does the media prefer ALUR or MLSS?

Summary

How does Allurion Technologies compare to Predictive Oncology?

Which has preferable valuation and earnings, POAI or ALUR?

Is POAI or ALUR more profitable?

Does the media refer more to POAI or ALUR?

Do insiders and institutionals have more ownership in POAI or ALUR?

Which has more risk & volatility, POAI or ALUR?

Do analysts recommend POAI or ALUR?

Summary

How does Allurion Technologies compare to Plus Therapeutics?

Does the media favor ALUR or PSTV?

Do insiders & institutionals believe in ALUR or PSTV?

Which has more risk and volatility, ALUR or PSTV?

Which has higher earnings & valuation, ALUR or PSTV?

Is ALUR or PSTV more profitable?

Do analysts prefer ALUR or PSTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALUR vs. The Competition

Allurion Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools